Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plasmapheresis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Plasmapheresis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-000641-33 Sponsor Protocol Number: PAX Start Date*: 2022-04-21
    Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
    Medical condition: Post-Acute-Covid-19 Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10021881 - Infections and infestations 10085503 Post-acute COVID-19 syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002817-37 Sponsor Protocol Number: PIX200701 Start Date*: 2008-07-29
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS
    Medical condition: Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028417 Myasthenia gravis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001995-71 Sponsor Protocol Number: PLATIG-1404 Start Date*: 2014-07-03
    Sponsor Name:Plazmaferezis Állomás Közhasznú Nonprofit Kft
    Full Title: Open label multicenter prospective trial to assess the tetanus titer in subject of regular plasmapharesis
    Medical condition: healthy subjects eligible for tetanus booster vaccination
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002711-94 Sponsor Protocol Number: HO124WM Start Date*: 2014-09-19
    Sponsor Name:HOVON Foundation
    Full Title: HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10054697 Waldenstrom's macroglobulinemia recurrent LLT
    21.1 100000004864 10054698 Waldenstrom's macroglobulinemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000726-11 Sponsor Protocol Number: SHP616-302 Start Date*: 2016-03-08
    Sponsor Name:Shire Viropharma, Inc.
    Full Title: A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney t...
    Medical condition: Acute Antibody Mediated Rejection (AMR) in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001598-25 Sponsor Protocol Number: IG1002 Start Date*: 2011-10-25
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intra...
    Medical condition: Mild to Moderate Alzheimer's Disease patients.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007019-33 Sponsor Protocol Number: RES.I.ST. EXPERIENCED Start Date*: 2008-12-24
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: IMMUNE TOLERANCE INDUCTION STUDY IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AFTER FAILURE OF A PREVIOUS INDUCTION OF IMMUNE TOLERANCE WITH FVIII CONCENTRATES WITHOUT VON WILLEBRAND F...
    Medical condition: SEVERE TYPE A HAEMOPHILIA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010432 Congenital deficiency of other clotting factors LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002179-34 Sponsor Protocol Number: SLE01_ENK Start Date*: 2005-08-10
    Sponsor Name:Euro Nippon Kayaku GmbH
    Full Title: SAFETY AND EFFICACY STUDY ON DEOXYSPERGUALIN (NKT-01) IN PATIENTS WITH UNCONTROLLED LUPUS NEPHRITIS RECEIVING ORAL CORTICOSTEROIDS AND PRIOR TREATMENT OF STANDARD IMMUNOSUPPRESSIVE THERAPY - a pros...
    Medical condition: Systemic lupus erythrematosus (SLE) is an aggressive autoimmune disease. The chronic inflammatory processes involve many organs like the skin, lung, kidneys, central and peripheral nervous system, ...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10025140 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008285-12 Sponsor Protocol Number: 1655/08 Start Date*: 2009-10-14
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PROSPECTIVE STUDY “IBDISC”: Regeneration and Immunity in patients affected by IBD undergoing immunomodulatory treatment and adjuvant role of G-CSF and/or plasmapheresis (Inflammatory Bowel Disease...
    Medical condition: Inflammatory bowel disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 PT
    9.1 10045282 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004998-53 Sponsor Protocol Number: OMB116024 Start Date*: 2013-02-05
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia.
    Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000441-12 Sponsor Protocol Number: 0624-201 Start Date*: 2012-09-21
    Sponsor Name:VIROPHARMA Incorporated
    Full Title: A randomized, double-blind, placebo-controlled pilot study to evaluate the safety and effect of Cinryze (C1 Esterase Inhibitor (Human)) for the treatment of acute antibody-mediated rejection in rec...
    Medical condition: Acute Antibody Mediated Rejection (AMR) in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10044439 Transplant rejection PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003022-32 Sponsor Protocol Number: CL012_140 Start Date*: 2019-10-12
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
    Medical condition: Primary Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001936-86 Sponsor Protocol Number: COMET Start Date*: 2020-10-19
    Sponsor Name:Hannover Medical School
    Full Title: A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19
    Medical condition: Hospitalized patients with mild SARS-CoV-2 infection (WHO R&D Blueprint Ordinal Scale for Clinical Improvement = 3 or 4)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-006060-89 Sponsor Protocol Number: NMSG29/21 Start Date*: 2021-03-26
    Sponsor Name:Odense University Hospital
    Full Title: Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe): An Investigator Sponsored Trial
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003563-31 Sponsor Protocol Number: 26866138CAN 2021 Start Date*: 2007-03-09
    Sponsor Name:European Myeloma Network
    Full Title: Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM).
    Medical condition: Newly diagnosed Waldenstrom's macroglobulinemia (WM)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054695 Waldenstrom's macroglobulinemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) NL (Ongoing) ES (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005732-29 Sponsor Protocol Number: MOM-M281-011 Start Date*: 2021-11-19
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generali...
    Medical condition: Myasthenia gravis (MG).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003627-30 Sponsor Protocol Number: 20170367744 Start Date*: 2018-06-27
    Sponsor Name:Odense Research Center for Anaphylaxis (ORCA)
    Full Title: Protection from food induced anaphylaxis by reducing serum level of specific IgE
    Medical condition: Food Allergy with Anaphylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10014315 Egg allergy LLT
    20.0 100000004870 10016709 Fish allergy LLT
    20.0 100000004870 10040539 Shellfish allergy LLT
    20.0 100000004870 10001745 Allergy to cow's milk LLT
    20.1 100000004870 10034202 Peanut allergy LLT
    20.0 100000004870 10027024 Meat allergy LLT
    20.0 100000004870 10011240 Cow's milk allergy LLT
    20.1 100000004870 10054957 Allergy to grains LLT
    20.1 100000004870 10054959 Allergy to nuts LLT
    20.0 100000004870 10064075 Seafood allergy LLT
    20.0 100000004870 10076438 Milk protein allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-000007-28 Sponsor Protocol Number: DSMMXII Start Date*: 2009-05-22
    Sponsor Name:Universitaetsklinikum Wuerzburg
    Full Title: Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016616-21 Sponsor Protocol Number: DSMMXIV Start Date*: 2011-10-20
    Sponsor Name:Wuerzburg University Hospital
    Full Title: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007016-15 Sponsor Protocol Number: RES.I.ST. NAÏVE Start Date*: 2008-12-24
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: RANDOMISED STUDY OF FIRST CHOICE IMMUNOTOLERANCE INDUCTION IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AT HIGH RISK OF FAILURE: COMPARISON OF INDUCTION OF IMMUNE TOLERANCE WITH FVIII ...
    Medical condition: SEVERE TYPE A HAEMOPHILIA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010432 Congenital deficiency of other clotting factors LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA